{"organizations": [], "uuid": "2101a709f654e8d9465a847a52604c4d8b90ee68", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-anthera-announces-positive-outcome/brief-anthera-announces-positive-outcome-of-second-interim-futility-analysis-in-the-phase-3-sollpura-study-idUSFWN1PH0UX", "country": "US", "domain_rank": 408, "title": "BRIEF-Anthera Announces Positive Outcome Of Second Interim Futility Analysis In The Phase 3 Sollpura Study", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-22T15:48:00.000+02:00", "replies_count": 0, "uuid": "2101a709f654e8d9465a847a52604c4d8b90ee68"}, "author": "", "url": "https://www.reuters.com/article/brief-anthera-announces-positive-outcome/brief-anthera-announces-positive-outcome-of-second-interim-futility-analysis-in-the-phase-3-sollpura-study-idUSFWN1PH0UX", "ord_in_thread": 0, "title": "BRIEF-Anthera Announces Positive Outcome Of Second Interim Futility Analysis In The Phase 3 Sollpura Study", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "anthera pharmaceuticals inc", "sentiment": "none"}, {"name": "sollpura study reuters staff", "sentiment": "none"}, {"name": "anthera pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 50 PM / Updated 5 minutes ago BRIEF-Anthera Announces Positive Outcome Of Second Interim Futility Analysis In The Phase 3 Sollpura Study Reuters Staff 1 Min Read \nJan 22 (Reuters) - Anthera Pharmaceuticals Inc: \n* ANTHERA ANNOUNCES POSITIVE OUTCOME OF SECOND INTERIM FUTILITY ANALYSIS IN THE PHASE 3 RESULT CLINICAL STUDY OF SOLLPURA: STUDY ON SCHEDULE FOR TOPLINE DATA THIS QUARTER \n* ANTHERA PHARMACEUTICALS INC - ON TRACK TO REPORT TOPLINE DATA LATER THIS QUARTERâ€‹ FROM RESULT STUDY Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-22T15:48:00.000+02:00", "crawled": "2018-01-22T16:01:47.004+02:00", "highlightTitle": ""}